TY - JOUR AU - Tourneau, C. AU - Lee, J. J. AU - Siu, L. L. PY - 2009 DA - 2009// TI - Dose escalation methods in phase I cancer clinical trials JO - J Natl Cancer Inst VL - 101 UR - https://doi.org/10.1093/jnci/djp079 DO - 10.1093/jnci/djp079 ID - Tourneau2009 ER - TY - JOUR AU - Eisenhauer, E. A. AU - O’Dwyer, P. J. AU - Christian, M. AU - Humphrey, J. S. PY - 2000 DA - 2000// TI - Phase I clinical trial design in cancer drug development JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 18 UR - https://doi.org/10.1200/JCO.2000.18.3.684 DO - 10.1200/JCO.2000.18.3.684 ID - Eisenhauer2000 ER - TY - JOUR AU - Tosi, D. AU - Laghzali, Y. AU - Vinches, M. AU - Alexandre, M. AU - Homicsko, K. AU - Fasolo, A. PY - 2015 DA - 2015// TI - Clinical development strategies and outcomes in first-in-human trials of monoclonal antibodies JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.1082 DO - 10.1200/JCO.2014.58.1082 ID - Tosi2015 ER - TY - JOUR AU - Paoletti, X. AU - Postel-Vinay, S. AU - Servois, V. AU - Doussau, A. AU - Ollivier, L. AU - Tourneau, C. PY - 2010 DA - 2010// TI - Dose finding methods for targeted agents: new perspectives JO - Bull Cancer (Paris) VL - 97 ID - Paoletti2010 ER - TY - JOUR AU - O’Quigley, J. AU - Pepe, M. AU - Fisher, L. PY - 1990 DA - 1990// TI - Continual reassessment method: a practical design for phase 1 clinical trials in cancer JO - Biometrics. VL - 46 UR - https://doi.org/10.2307/2531628 DO - 10.2307/2531628 ID - O’Quigley1990 ER - TY - JOUR AU - Piantadosi, S. AU - Liu, G. PY - 1996 DA - 1996// TI - Improved designs for dose escalation studies using pharmacokinetic measurements JO - Stat Med VL - 15 UR - https://doi.org/3.0.CO;2-2 DO - 3.0.CO;2-2 ID - Piantadosi1996 ER - TY - JOUR AU - Braun, T. M. PY - 2002 DA - 2002// TI - The bivariate continual reassessment method. Extending the CRM to phase I trials of two competing outcomes JO - Control Clin Trials VL - 23 UR - https://doi.org/10.1016/S0197-2456(01)00205-7 DO - 10.1016/S0197-2456(01)00205-7 ID - Braun2002 ER - TY - JOUR AU - Bekele, B. N. AU - Shen, Y. PY - 2005 DA - 2005// TI - A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial JO - Biometrics. VL - 61 UR - https://doi.org/10.1111/j.1541-0420.2005.00314.x DO - 10.1111/j.1541-0420.2005.00314.x ID - Bekele2005 ER - TY - JOUR AU - Dragalin, V. AU - Fedorov, V. PY - 2006 DA - 2006// TI - Adaptive designs for dose-finding based on efficacy–toxicity response JO - J Stat Plan Inference. VL - 136 UR - https://doi.org/10.1016/j.jspi.2005.08.005 DO - 10.1016/j.jspi.2005.08.005 ID - Dragalin2006 ER - TY - JOUR AU - Dragalin, V. AU - Fedorov, V. AU - Wu, Y. PY - 2008 DA - 2008// TI - Adaptive designs for selecting drug combinations based on efficacy–toxicity response JO - J Stat Plan Inference VL - 138 UR - https://doi.org/10.1016/j.jspi.2007.06.017 DO - 10.1016/j.jspi.2007.06.017 ID - Dragalin2008 ER - TY - JOUR AU - Houede, N. AU - Thall, P. F. AU - Nguyen, H. AU - Paoletti, X. AU - Kramar, A. PY - 2010 DA - 2010// TI - Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials JO - Biometrics. VL - 66 UR - https://doi.org/10.1111/j.1541-0420.2009.01302.x DO - 10.1111/j.1541-0420.2009.01302.x ID - Houede2010 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - PRISMA group JO - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med VL - 6 ID - Moher2009 ER - TY - JOUR AU - Moher, D. AU - Shamseer, L. AU - Clarke, M. AU - Ghersi, D. AU - Liberati, A. PY - 2015 DA - 2015// TI - Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement JO - Syst Rev VL - 4 UR - https://doi.org/10.1186/2046-4053-4-1 DO - 10.1186/2046-4053-4-1 ID - Moher2015 ER - TY - JOUR AU - Recchia, F. AU - Filippis, S. AU - Rosselli, M. AU - Saggio, G. AU - Cesta, A. AU - Fumagalli, L. PY - 2001 DA - 2001// TI - Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer JO - Clin Cancer Res Off J Am Assoc Cancer Res VL - 7 ID - Recchia2001 ER - TY - JOUR AU - Parihar, R. PY - 2004 DA - 2004// TI - A phase I study of interleukin 12 with Trastuzumab in patients with human epidermal growth factor Receptor-2-overexpressing malignancies: analysis of sustained interferon production in a subset of patients JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-04-0265 DO - 10.1158/1078-0432.CCR-04-0265 ID - Parihar2004 ER - TY - JOUR AU - Wages, N. A. AU - Slingluff, C. L. AU - Petroni, G. R. PY - 2015 DA - 2015// TI - A phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma JO - Contemp Clin Trials VL - 41 UR - https://doi.org/10.1016/j.cct.2015.01.016 DO - 10.1016/j.cct.2015.01.016 ID - Wages2015 ER - TY - JOUR AU - Cebon, J. AU - Jäger, E. AU - Shackleton, M. J. AU - Gibbs, P. AU - Davis, I. D. AU - Hopkins, W. PY - 2003 DA - 2003// TI - Two phase I studies of low dose recombinant human IL-12 with Melan-a and influenza peptides in subjects with advanced malignant melanoma JO - Cancer Immun VL - 3 ID - Cebon2003 ER - TY - JOUR AU - Yau, T. AU - Cheng, P. N. AU - Chan, P. AU - Chan, W. AU - Chen, L. AU - Yuen, J. PY - 2013 DA - 2013// TI - A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (peg-rhArg1) in patients with advanced hepatocellular carcinoma JO - Investig New Drugs VL - 31 UR - https://doi.org/10.1007/s10637-012-9807-9 DO - 10.1007/s10637-012-9807-9 ID - Yau2013 ER - TY - JOUR AU - Wolchok, J. D. AU - Williams, L. AU - Pinto, J. T. AU - Fleisher, M. AU - Krown, S. E. AU - Hwu, W. -. J. PY - 2003 DA - 2003// TI - Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma JO - Melanoma Res VL - 13 UR - https://doi.org/10.1097/00008390-200304000-00013 DO - 10.1097/00008390-200304000-00013 ID - Wolchok2003 ER - TY - JOUR AU - Geevarghese, S. K. AU - Geller, D. A. AU - Haan, H. A. AU - Hörer, M. AU - Knoll, A. E. AU - Mescheder, A. PY - 2010 DA - 2010// TI - Phase I/II study of Oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal Cancer metastatic to the liver JO - Hum Gene Ther VL - 21 UR - https://doi.org/10.1089/hum.2010.020 DO - 10.1089/hum.2010.020 ID - Geevarghese2010 ER - TY - JOUR AU - Miyamoto, T. AU - Yamamoto, N. AU - Nishimura, H. AU - Koto, M. AU - Tsujii, H. AU - Mizoe, J. PY - 2003 DA - 2003// TI - Carbon ion radiotherapy for stage I non-small cell lung cancer JO - Radiother Oncol VL - 66 UR - https://doi.org/10.1016/S0167-8140(02)00367-5 DO - 10.1016/S0167-8140(02)00367-5 ID - Miyamoto2003 ER - TY - STD TI - Combs SE, Habermehl D, Ganten T, Schmidt J, Edler L, Burkholder I, et al. Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer. 2011;11. https://doi.org/10.1186/1471-2407-11-67. ID - ref22 ER - TY - STD TI - Makishima H, Yasuda S, Isozaki Y, Kasuya G, Okada N, Miyazaki M, et al. Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: A dose escalation study. Cancer Sci. 2018; cas.13872. ID - ref23 ER - TY - JOUR AU - Neste, E. AU - Cazin, B. AU - Janssens, A. AU - González-Barca, E. AU - Terol, M. J. AU - Levy, V. PY - 2013 DA - 2013// TI - Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study JO - Cancer Chemother Pharmacol VL - 71 UR - https://doi.org/10.1007/s00280-012-2033-5 DO - 10.1007/s00280-012-2033-5 ID - Neste2013 ER - TY - JOUR AU - Wages, N. A. AU - Portell, C. A. AU - Williams, M. E. AU - Conaway, M. R. AU - Petroni, G. R. PY - 2017 DA - 2017// TI - Implementation of a model-based Design in a Phase Ib Study of combined targeted agents JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-1069 DO - 10.1158/1078-0432.CCR-17-1069 ID - Wages2017 ER - TY - JOUR AU - Rodgers, K. E. AU - Oliver, J. AU - Zerega, G. S. PY - 2006 DA - 2006// TI - Phase I/II dose escalation study of angiotensin 1–7 [A(1–7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer JO - Cancer Chemother Pharmacol VL - 57 UR - https://doi.org/10.1007/s00280-005-0078-4 DO - 10.1007/s00280-005-0078-4 ID - Rodgers2006 ER - TY - JOUR AU - Cassier, P. A. AU - Italiano, A. AU - Gomez-Roca, C. A. AU - Tourneau, C. AU - Toulmonde, M. AU - Cannarile, M. A. PY - 2015 DA - 2015// TI - CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00132-1 DO - 10.1016/S1470-2045(15)00132-1 ID - Cassier2015 ER - TY - JOUR AU - Vadhan-Raj, S. AU - Verschraegen, C. F. AU - Bueso-Ramos, C. AU - Broxmeyer, H. E. AU - Kudelka, A. P. AU - Freedman, R. S. PY - 2000 DA - 2000// TI - Recombinant human Thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic Cancer JO - Ann Intern Med VL - 132 UR - https://doi.org/10.7326/0003-4819-132-5-200003070-00005 DO - 10.7326/0003-4819-132-5-200003070-00005 ID - Vadhan-Raj2000 ER - TY - JOUR AU - Mammoliti, S. AU - Andretta, V. AU - Bennicelli, E. AU - Caprioni, F. AU - Comandini, D. AU - Fornarini, G. PY - 2011 DA - 2011// TI - Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdq436 DO - 10.1093/annonc/mdq436 ID - Mammoliti2011 ER - TY - STD TI - Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YYM. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. BMC Cancer. 2013;13. https://doi.org/10.1186/1471-2407-13-121. ID - ref30 ER - TY - JOUR AU - Gregorc, V. AU - Citterio, G. AU - Vitali, G. AU - Spreafico, A. AU - Scifo, P. AU - Borri, A. PY - 2010 DA - 2010// TI - Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours JO - Eur J Cancer VL - 46 UR - https://doi.org/10.1016/j.ejca.2009.10.005 DO - 10.1016/j.ejca.2009.10.005 ID - Gregorc2010 ER - TY - JOUR AU - Hariharan, S. AU - Gustafson, D. AU - Holden, S. AU - McConkey, D. AU - Davis, D. AU - Morrow, M. PY - 2007 DA - 2007// TI - Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors JO - Ann Oncol VL - 18 UR - https://doi.org/10.1093/annonc/mdm140 DO - 10.1093/annonc/mdm140 ID - Hariharan2007 ER - TY - JOUR AU - Reckamp, K. L. PY - 2006 DA - 2006// TI - A phase I trial to determine the optimal biological dose of Celecoxib when combined with Erlotinib in advanced non-small cell lung Cancer JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0112 DO - 10.1158/1078-0432.CCR-06-0112 ID - Reckamp2006 ER - TY - JOUR AU - Jamieson, D. AU - Griffin, M. J. AU - Sludden, J. AU - Drew, Y. AU - Cresti, N. AU - Swales, K. PY - 2016 DA - 2016// TI - A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours JO - Eur J Cancer VL - 68 UR - https://doi.org/10.1016/j.ejca.2016.08.026 DO - 10.1016/j.ejca.2016.08.026 ID - Jamieson2016 ER - TY - STD TI - Toma S, Raffo P, Nicolo G, Canavese G, Margallo E, Vecchio C, et al. Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients. Int J Oncol. 2000. https://doi.org/10.3892/ijo.17.5.991. ID - ref35 ER - TY - JOUR AU - Wages, N. A. AU - Chiuzan, C. AU - Panageas, K. S. PY - 2018 DA - 2018// TI - Design considerations for early-phase clinical trials of immune-oncology agents JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0389-8 DO - 10.1186/s40425-018-0389-8 ID - Wages2018 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Colin, P. AU - Delattre, M. AU - Minini, P. AU - Micallef, S. PY - 2017 DA - 2017// TI - An escalation for bivariate binary endpoints controlling the risk of Overtoxicity (EBE-CRO): managing efficacy and toxicity in early oncology clinical trials JO - J Biopharm Stat VL - 27 UR - https://doi.org/10.1080/10543406.2017.1295248 DO - 10.1080/10543406.2017.1295248 ID - Colin2017 ER - TY - STD TI - Altzerinakou M-A, Paoletti X. An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncology. Stat Methods Med Res. 2019;096228021983773. ID - ref39 ER - TY - JOUR AU - Cook, N. AU - Hansen, A. R. AU - Siu, L. L. AU - Abdul Razak, A. R. PY - 2015 DA - 2015// TI - Early phase clinical trials to identify optimal dosing and safety JO - Mol Oncol VL - 9 UR - https://doi.org/10.1016/j.molonc.2014.07.025 DO - 10.1016/j.molonc.2014.07.025 ID - Cook2015 ER -